vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.
SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs -0.8%, a 8.3% gap on every dollar of revenue. On growth, SIFCO INDUSTRIES INC posted the faster year-over-year revenue change (14.8% vs -25.7%). SIFCO INDUSTRIES INC produced more free cash flow last quarter ($8.0M vs $-15.8M). Over the past eight quarters, SIFCO INDUSTRIES INC's revenue compounded faster (8.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.
CTMX vs SIF — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $24.0M |
| Net Profit | $-154.0K | $1.8M |
| Gross Margin | — | 21.6% |
| Operating Margin | -6.9% | 10.7% |
| Net Margin | -0.8% | 7.5% |
| Revenue YoY | -25.7% | 14.8% |
| Net Profit YoY | 97.6% | 177.3% |
| EPS (diluted) | — | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $24.0M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | $18.7M | $22.1M | ||
| Q1 25 | $50.9M | $19.0M | ||
| Q4 24 | $38.1M | $20.9M | ||
| Q3 24 | $33.4M | $21.7M | ||
| Q2 24 | $25.1M | $22.0M | ||
| Q1 24 | $41.5M | $20.5M |
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-429.0K | ||
| Q2 25 | $-154.0K | $3.4M | ||
| Q1 25 | $23.5M | $-1.4M | ||
| Q4 24 | $18.9M | $-2.3M | ||
| Q3 24 | $5.7M | $-443.0K | ||
| Q2 24 | $-6.5M | $72.0K | ||
| Q1 24 | $13.8M | $-1.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | 12.3% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | -1.7% | ||
| Q2 25 | -6.9% | 14.8% | ||
| Q1 25 | 44.4% | -4.1% | ||
| Q4 24 | 46.4% | -9.2% | ||
| Q3 24 | 12.3% | -1.5% | ||
| Q2 24 | -33.7% | 0.7% | ||
| Q1 24 | 28.1% | -6.5% |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | -1.9% | ||
| Q2 25 | -0.8% | 15.4% | ||
| Q1 25 | 46.2% | -7.3% | ||
| Q4 24 | 49.6% | -11.1% | ||
| Q3 24 | 17.2% | -2.0% | ||
| Q2 24 | -26.0% | 0.3% | ||
| Q1 24 | 33.3% | -7.8% |
| Q4 25 | — | $0.29 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $1.1M |
| Total DebtLower is stronger | — | $39.0K |
| Stockholders' EquityBook value | $119.9M | $38.7M |
| Total Assets | $175.1M | $74.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $491.0K | ||
| Q2 25 | $49.0M | $2.0M | ||
| Q1 25 | $47.6M | $1.9M | ||
| Q4 24 | $38.1M | $3.1M | ||
| Q3 24 | $40.6M | $1.7M | ||
| Q2 24 | $43.2M | $3.4M | ||
| Q1 24 | $36.2M | $2.5M |
| Q4 25 | — | $39.0K | ||
| Q3 25 | — | $51.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | — | $38.7M | ||
| Q3 25 | — | $36.9M | ||
| Q2 25 | $119.9M | $35.8M | ||
| Q1 25 | $25.0M | $32.4M | ||
| Q4 24 | $-456.0K | $33.7M | ||
| Q3 24 | $-23.5M | $30.4M | ||
| Q2 24 | $-31.2M | $29.8M | ||
| Q1 24 | $-31.7M | $29.7M |
| Q4 25 | — | $74.9M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | $175.1M | $77.3M | ||
| Q1 25 | $98.5M | $78.8M | ||
| Q4 24 | $120.5M | $81.0M | ||
| Q3 24 | $139.0M | $104.6M | ||
| Q2 24 | $159.2M | $106.3M | ||
| Q1 24 | $184.7M | $104.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $8.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $8.0M |
| FCF MarginFCF / Revenue | -84.6% | 33.3% |
| Capex IntensityCapex / Revenue | 0.1% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 4.51× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.1M | ||
| Q3 25 | — | $726.0K | ||
| Q2 25 | $-15.8M | $371.0K | ||
| Q1 25 | $-21.0M | $2.8M | ||
| Q4 24 | $-19.9M | $-3.8M | ||
| Q3 24 | $-20.7M | $857.0K | ||
| Q2 24 | $-19.5M | $382.0K | ||
| Q1 24 | $-26.0M | $-3.2M |
| Q4 25 | — | $8.0M | ||
| Q3 25 | — | $566.0K | ||
| Q2 25 | $-15.8M | $310.0K | ||
| Q1 25 | $-21.2M | $2.7M | ||
| Q4 24 | $-20.0M | $-3.9M | ||
| Q3 24 | $-20.7M | $580.0K | ||
| Q2 24 | $-19.6M | $-175.0K | ||
| Q1 24 | $-26.2M | $-3.9M |
| Q4 25 | — | 33.3% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | -84.6% | 1.4% | ||
| Q1 25 | -41.6% | 14.1% | ||
| Q4 24 | -52.5% | -18.8% | ||
| Q3 24 | -62.1% | 2.7% | ||
| Q2 24 | -78.2% | -0.8% | ||
| Q1 24 | -63.1% | -18.9% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.2% | 0.5% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.4% | 2.5% | ||
| Q1 24 | 0.3% | 3.3% |
| Q4 25 | — | 4.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | 5.31× | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SIF
| Fixed Wing Aircraft Revenue | $10.5M | 44% |
| Commercial Revenue | $8.7M | 36% |
| Commercial Product And Other Revenue | $2.8M | 12% |
| Commercial Space | $1.1M | 5% |
| Other | $840.0K | 4% |
